Growth factors in acute myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 1, 2001, Pages 175-187

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

G CSF; GM CSF; PEG RHMDGF; Priming; Supportive care

Indexed keywords

ANTIBIOTIC AGENT; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; AZIRIDINYLBENZOQUINONE; COLONY STIMULATING FACTOR; CYTARABINE; CYTOKINE; CYTOKINE RECEPTOR; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IDARUBICIN; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE PAIN; CANCER MORTALITY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE BLIND PROCEDURE; DRUG TARGETING; FEVER; GRANULOCYTE; GRANULOCYTE TRANSFUSION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HUMAN CELL; HYPOTHESIS; INFECTION; MAJOR CLINICAL STUDY; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035040596     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2000.0122     Document Type: Article

References (44)

1. Hematopoietic growth factors as adjuncts to the treatment of acutemyeloid leukemia
2. Use of cytokines in the treatment of acute myelocytic leukemia: A critical review
3. Hematopoietic growth factors in acute leukemia
4. Application of myeloid growth factors in the treatment of acute myeloid leukemia
5. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
6. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (EI490)
7. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
8. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study
9. A randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia
10. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer Study 9022
11. Granulocyte colony stimulating factor after intensive chemotherapy limits early mortality in elderly patients with newly diagnosed acute myelogenous leukemia
12. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group
13. Effects of lenograstim (glycosylated huG-CSF) after high dose cytarabine-based induction chemotherapy for adult acute myeloid leukemia (AML)
14. The value of difference modalities of GM-CSF applied during or after induction therapy of acute myeloid leukemia
15. Use of recombinant granulocyte-macrophage colony-stimulating-factor (GM-CSF) during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of randomised study of the EORTC-LCG and HOVON Groups
16. GM-CSF in double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML)
17. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML)
18. Hematopoietic growth factors in acute myeloid leukemia
19. A phase III study of priming with yeast-derived granulocyte-macrophage colony-stimulating-factor (rhuGM-CSF) for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): A study of the Eastern Cooperative Oncology Group
20. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor
21. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia in higher age or after relapse
22. In vivo effects of GM-CSF before, during and after sequential chemotherapy on platelet- and reticulocyte-recovery
23. Survivorship analysis for clinical studies
24. Economic analysis of granulocyte colony stimulating factor (G-CSF) as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group (SWOG) clinical trial
25. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia
26. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia
27. Treatment of newly diagnosed acute mylogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF
28. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with cytarabine without granulocyte colony-stimulating factor
29. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity
30. Effect of granulocyte macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia
31. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia
32. Regulation and synthesis of bcl-2 protein by growth factors
33. Cytogenetic subgroups of acute myeloid leukemia (AML) differ significantly in proliferative activity, cytokine production and sensitivity to GM-CSF stimulation
34. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation
35. Some extensions and applications of a bayesian strategy for monitoring multiple outcomes in clinical trials
36. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia
37. Frequency of prolonged remission duration after high-dose cytosine arabinoside intestification in AML varies by cytogenetic subtype
38. Evaluation and comparison of three mobilization methods for granulocyte collection
39. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis
40. Cytotoxicity of diptheria toxin-granulocyte macrophage colony stimulating factor (DT-GMCSF) fusion protein for acute-myelogenous leukemia (AML) stem cells
41. The majority of adult patients with acute myeloid leukemia (AML) have low to undetectable concentrations of antibodies against DTGM, a novel fusion toxin consisting of truncated diptheria toxin (DT) linked to human macrophage colony stimulating factor (GM)
42. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
43. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group
44. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes